Latest Regulatory News

Page 530 of 906
DGL Group Limited reported a 3% revenue increase to $481.5 million for FY25 but swung to a $24.6 million net loss driven by asset impairments and operational challenges. The company is undertaking significant restructuring and integration efforts to restore profitability.
Victor Sage
Victor Sage
29 Aug 2025
Staude Capital Global Value Fund Limited has announced a fully franked ordinary dividend of AUD 0.033 per share for the half-year ending June 2025, accompanied by a dividend reinvestment plan offering a 2.5% discount.
Claire Turing
Claire Turing
29 Aug 2025
MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.
Ada Torres
Ada Torres
29 Aug 2025
Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.
Ada Torres
Ada Torres
29 Aug 2025
4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.
Ada Torres
Ada Torres
29 Aug 2025
4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.
Ada Torres
Ada Torres
29 Aug 2025
Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.
Victor Sage
Victor Sage
29 Aug 2025
Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.
Ada Torres
Ada Torres
29 Aug 2025
Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.
Claire Turing
Claire Turing
29 Aug 2025
Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.
Ada Torres
Ada Torres
29 Aug 2025
Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.
Ada Torres
Ada Torres
29 Aug 2025
FlexiRoam Limited reported an 8.6% revenue decline for FY25 but achieved a remarkable turnaround in the second half, posting positive EBITDA and net profit after a CEO-led operational reset.
Sophie Babbage
Sophie Babbage
29 Aug 2025